Related News

Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
See All